The Kable

The Kable

Friday Kable

💉 A potential threat to the world's generics supply; Pfizer, BioNTech's promising combo vaccine; Sanofi's spin-off of its consumer health business

#459 | Malarial protein discoveries; A phage diet for cells; Migraines in your genes

Ria's avatar
Vinod's avatar
Ria
and
Vinod
Oct 27, 2023
∙ Paid

Hello, and welcome to our free Friday edition of The Kable. Today, we kick things off with good news on the respiratory virus vaccine front. Pfizer and BioNTech have announced positive results from phase 1/2 studies of their mRNA-based combo vaccine, which generated robust immune responses to influenza A, influenza B, and SARS-CoV-2 strains. A phase 3 t…

Keep reading with a 7-day free trial

Subscribe to The Kable to keep reading this post and get 7 days of free access to the full post archives.

Already a paid subscriber? Sign in
© 2025 The Kable · Privacy ∙ Terms ∙ Collection notice
Start your SubstackGet the app
Substack is the home for great culture